Bethesda, Maryland Saturday, March 15, 2025, 10:00 Hrs [IST] ...
Severe mpox and long-term sequelae such as severe scarring were more likely to occur among HIV-positive patients with detectable viral loads and low CD4 counts.
The antiviral drug tecovirimat used without other antivirals did not reduce the time to clinical resolution of clade II mpox ...
10d
A NEW mutant strain of mpox discovered in the Democratic Republic of Congo could be better at spreading between people, ...
A NIH-led trial found tecovirimat ineffective in reducing mpox lesion healing time or pain relief. The study was halted in 2024, with findings presented at CROI 2025.
Africanews on MSN6d
Mpox outbreak hits Kabare amid ongoing conflict in DRCMpox is rapidly spreading in Kabare, South Kivu, as healthcare systems struggle amidst ongoing conflict in eastern DRC ...
More than 200 community health agents have already been trained in Burundi to help control the spread of mpox as the ...
The antiviral drug tecovirimat used without other antivirals did not reduce the time to clinical resolution of clade II mpox ...
NIH-sponsored trial data offers further evidence to help inform mpox treatment decisions.
The antiviral drug tecovirimat used without other antivirals did not reduce the time to clinical resolution of clade II mpox lesions or improve ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback